Insider Buying and $670 M Capital Raise Propel Dianthus Therapeutics Toward Milestone Success
Insider buying, a $670 M public offering and a fast‑track monoclonal antibody platform signal strong investor confidence in Dianthus Therapeutics, but careful watch on dilution, R&D progress and FDA approval is essential for long‑term upside.
5 minutes to read